Cargando…
Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients
SIMPLE SUMMARY: Despite rapid progress in the research on epithelial ovarian cancer (EOC), it is usually diagnosed during the advanced stage with only 30% of patients surviving longer than 5 years. This is the first study in which the whole CXCR4-CXCL12-CXCR7 axis was systematically evaluated in tum...
Autores principales: | D’Alterio, Crescenzo, Spina, Anna, Arenare, Laura, Chiodini, Paolo, Napolitano, Maria, Galdiero, Francesca, Portella, Luigi, Simeon, Vittorio, Signoriello, Simona, Raspagliesi, Francesco, Lorusso, Domenica, Pisano, Carmela, Colombo, Nicoletta, Zannoni, Gian Franco, Losito, Nunzia Simona, De Cecio, Rossella, Scognamiglio, Giosuè, Califano, Daniela, Russo, Daniela, Tuninetti, Valentina, Piccirillo, Maria Carmela, Gargiulo, Piera, Perrone, Francesco, Pignata, Sandro, Scala, Stefania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997727/ https://www.ncbi.nlm.nih.gov/pubmed/35406620 http://dx.doi.org/10.3390/cancers14071849 |
Ejemplares similares
-
CXCR4 expression affects overall survival of HCC patients whereas CXCR7 expression does not
por: Neve Polimeno, Maria, et al.
Publicado: (2015) -
Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study
por: Califano, Daniela, et al.
Publicado: (2021) -
Inhibition of stromal CXCR4 impairs development of lung metastases
por: D’Alterio, Crescenzo, et al.
Publicado: (2012) -
CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients
por: D’Alterio, Crescenzo, et al.
Publicado: (2022) -
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial
por: Capoluongo, E.D., et al.
Publicado: (2022)